FINWIRES · TerminalLIVE
FINWIRES

Morguard Reports Higher Profit, Lower Revenue for First Quarter; Dividend Declared

By

-- Morguard (MRC.TO) after trade Tuesday said its first-quarter profit rose while revenue dropped year-over-year.

The company earned $61.2 million in the quarter ended March 31, up from $54.8 million a year ago, "primarily due to an increase in non-cash net fair value gain, partially offset by lower net operating income".

Revenue fell to $275.1 million from $282.2 million a year ago. Revenue from real estate properties fell to $254.5 million from $263.1 million, while revenue from hotel properties rose to $6.9 million from $5.4 million.

Among other highlights, NOI was $86.9 million, down from $90.1 million in the prior year period. Funds from operations totaled $39.6 million, or $3.71 per share, down from $47.2 million, or $4.41 per share, a year prior. FactSet expected FFO per share of $3.92.

The company also announced second-quarter dividend of $0.20 per common share, payable on June 30, to shareholders of record at the close of business on June 15.

Morguard shares last traded Monday, closing at $120.15 on the Toronto Stock Exchange,

Related Articles

Asia

Cofoe Medical Technology Nets HK$1 Billion From Hong Kong IPO Ahead of Debut

Cofoe Medical Technology (HKG:1187, SHE:301087) raised HK$1.01 billion in net proceeds from its initial public offering in Hong Kong.The offer price was set at HK$39.33 per H-share, according to a Tuesday after-market filing with the Hong Kong Stock Exchange.The China-based home care medical device provider offered 27 million H-shares in the global offering.The Hong Kong public offer was 399.08 times subscribed, with 2.7 million shares allocated, representing 10% of the total offering.The international offering was 3.4 times subscribed, with 24.3 million shares allocated, accounting for 90% of the total offering.Cornerstone investors, including Lens Technology (HK), Changsha Yufeng Technology, Vision Capital, and Panjing Harbourview Investment Fund, were allocated about 9.7 million shares in the international tranche, according to the filing.Cofoe Medical is scheduled to begin trading in Hong Kong on Wednesday, May 6.

$HKG:1187$SHE:301087
Insider Trading

Cytokinetics Insider Sold Shares Worth $270,795, According to a Recent SEC Filing

Fady Ibraham Malik, Executive Vice President, Research & Development, on May 05, 2026, sold 3,500 shares in Cytokinetics (CYTK) for $270,795. Following the Form 4 filing with the SEC, Malik has control over a total of 153,902 common shares of the company, with 153,902 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1061983/000106198326000051/xslF345X05/form4.xml

$CYTK
Mining & Metals

Correction: -- Pan American Silver Targets Up to US$1B in Shareholder Returns in 2026 Through Enhanced Shareholder Return Framework

$PAAS.TO